{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:56:57Z","timestamp":1767142617521,"version":"build-2238731810"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"This study is supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Erenumab is co-developed by Amgen and Novartis."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s12325-021-01677-y","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T15:02:52Z","timestamp":1616598172000},"page":"2921-2934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1448-6190","authenticated-orcid":false,"given":"Juanzhi","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Korrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Cheadle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshani","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matias L.","family":"Ferraris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Lopez-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"1677_CR1","unstructured":"Migraine Research Foundation. Migraine Fact Sheet 2020. https:\/\/migraineresearchfoundation.org\/about-migraine\/migraine-facts\/. Accessed 01 Jul 2020."},{"key":"1677_CR2","doi-asserted-by":"publisher","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496\u2013505. https:\/\/doi.org\/10.1111\/head.13281.","DOI":"10.1111\/head.13281"},{"key":"1677_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s13311-017-0592-1","volume":"15","author":"JJY Ong","year":"2018","unstructured":"Ong JJY, De Felice M. Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics. 2018;15:274\u201390.","journal-title":"Neurotherapeutics"},{"key":"1677_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.ncl.2019.07.006","volume":"37","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ. Acute treatment of migraine. Neurol Clin. 2019;37:727\u201342.","journal-title":"Neurol Clin"},{"key":"1677_CR5","unstructured":"American Migraine Foundation. Preventive treatments. 2016. https:\/\/americanmigrainefoundation.org\/understanding-migraine\/preventive-treatments\/. Accessed 10 Jul 2020."},{"issue":"4, Headache","key":"1677_CR6","first-page":"1052","volume":"24","author":"TJ Schwedt","year":"2018","unstructured":"Schwedt TJ. Preventive therapy of migraine. Continuum (Minneap Minn). 2018;24(4, Headache):1052\u201365.","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"1677_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1474-4422(10)70005-3","volume":"9","author":"PJ Goadsby","year":"2010","unstructured":"Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010;9(3):285\u201398.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1677_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41582-018-0104-x","volume":"14","author":"C Ridler","year":"2018","unstructured":"Ridler C. Erenumab succeeds in alleviating migraine where other treatments fail. Nat Rev Neurol. 2018;14(12):691.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"1677_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470\u201385.","journal-title":"Cephalalgia"},{"issue":"3","key":"1677_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0333102418821662","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019;39(3):445\u201358.","journal-title":"Cephalalgia"},{"issue":"1","key":"1677_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s10194-019-1000-5","volume":"20","author":"C Tiseo","year":"2019","unstructured":"Tiseo C, Ornello R, Pistoia F, Sacco S. How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice. J Headache Pain. 2019;20(1):49.","journal-title":"J Headache Pain"},{"issue":"1","key":"1677_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.115.227793","volume":"356","author":"L Shi","year":"2016","unstructured":"Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356(1):223\u201331.","journal-title":"J Pharmacol Exp Ther"},{"key":"1677_CR13","unstructured":"Aimovig\u2122 United States prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761077s000lbl.pdf. Accessed 29 Jun 2020."},{"key":"1677_CR14","unstructured":"Aimovig\u2122 Summary of product characteristics. https:\/\/www.ema.europa.eu\/documents\/product-information\/aimovig-epar-product-information_en.pdf. Accessed 29 Jun 2020."},{"issue":"22","key":"1677_CR15","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123\u201332.","journal-title":"N Engl J Med"},{"issue":"6","key":"1677_CR16","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"8","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;8(6):1026\u201337.","journal-title":"Cephalalgia"},{"issue":"10161","key":"1677_CR17","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280\u20137.","journal-title":"Lancet"},{"issue":"6","key":"1677_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425\u201334.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1677_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4103\/picr.PICR_36_18","volume":"9","author":"VR Suvarna","year":"2018","unstructured":"Suvarna VR. Real world evidence (RWE)\u2014are we (RWE) ready? Perspect Clin Res. 2018;9(2):61.","journal-title":"Perspect Clin Res"},{"key":"1677_CR20","first-page":"1","volume":"15","author":"M Bonafede","year":"2020","unstructured":"Bonafede M, McMorrow D, Noxon V, Desai P, Sapra S, Silberstein S. Care among migraine patients in a commercially insured population. Neurol Ther. 2020;15:1\u20131.","journal-title":"Neurol Ther"},{"issue":"1","key":"1677_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/03007995.2019.1657716","volume":"36","author":"JH Ford","year":"2020","unstructured":"Ford JH, Schroeder K, Buse DC, et al. Predicting initiation of preventive migraine medications: exploratory study in a large US medical claims database. Curr Med Res Opin. 2020;36(1):51\u201361.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1677_CR22","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1177\/0333102419851855","volume":"39","author":"JL Meyers","year":"2019","unstructured":"Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019;39(12):1518\u201334.","journal-title":"Cephalalgia"},{"issue":"1","key":"1677_CR23","first-page":"46","volume":"25","author":"JH Ford","year":"2019","unstructured":"Ford JH, Schroeder K, Nyhuis AW, et al. Cycling through migraine preventive treatments: implications for all-cause total direct costs and disease-specific costs. J Manag Care Spec Pharm. 2019;25(1):46\u201355b.","journal-title":"J Manag Care Spec Pharm"}],"updated-by":[{"DOI":"10.1007\/s12325-021-01837-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000}},{"DOI":"10.1007\/s12325-021-01744-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01677-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01677-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01677-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T15:12:41Z","timestamp":1626534761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01677-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1677"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01677-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"31 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-021-01837-0","URL":"https:\/\/doi.org\/10.1007\/s12325-021-01837-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-021-01744-4","URL":"https:\/\/doi.org\/10.1007\/s12325-021-01744-4","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}